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More than 30 years of genetic research on the CYP2C19 gene alone has identified approxi-
mately 2,000 reference single nucleotide polymorphisms (rsSNPs) containing 28 registered
alleles in the P450 Allele Nomenclature Committee and the number continues to increase.
However, knowledge of CYP2C19 SNPs remains limited with respect to biological func-
tions. Functional information on the variant is essential for justifying its clinical use. Only
common variants (minor allele frequency >5%) that represent CYP2C19∗2, ∗3, ∗17, and
others have been mostly studied. Discovery of new genetic variants is outstripping the gen-
eration of knowledge on the biological meanings of existing variants. Alternative strategies
may be needed to fill this gap. The present study summarizes up-to-date knowledge on
functional CYP2C19 variants discovered in phenotyped humans studied at the molecular
level in vitro. Understanding the functional meanings of CYP2C19 variants is an essen-
tial step toward shifting the current medical paradigm to highly personalized therapeutic
regimens.
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INTRODUCTION
Pharmacogenetics incorporates genetic information into clini-
cal decision making to avoid adverse drug effects and improve
drug efficacy. Drug responses can be affected by three major fac-
tors: pharmacokinetics, pharmacodynamics, and the underlying
molecular mechanisms of disease. Because the DNA sequence
of CYP2C19 is highly polymorphic, this may account for much
of the variability in the pharmacokinetics of drugs metabolized
by CYP2C19. CYP2C19 metabolizes a number of drugs, includ-
ing the antiulcer drug omeprazole (Andersson et al., 1992), the
antiplatelet drug clopidogrel (Mills et al., 1992), the anticonvul-
sant mephenytoin (Andersson et al., 1992; Bertilsson, 1995), the
antimalarial drug proguanil (Helsby et al., 1991; Ward et al., 1991),
the anxiolytic drug diazepam (Bertilsson, 1995; Wan et al., 1996;
Qin et al., 1999), and certain antidepressants such as citalopram
(Sindrup et al., 1993), imipramine (Skjelbo et al., 1991), amitripty-
line (Bouman et al., 2011), and clomipramine (Nielsen et al., 1994).
The phenotype of CYP2C19 metabolic capacity can be categorized
based on genotypes and includes extensive metabolizers (EM, two
wild-type functional alleles), intermediate metabolizers (IM, two
reduced functional alleles or one null allele and a functional allele),
and poor metabolizers (PM, two non-functional alleles) of drugs.
Undesirable side effects such as prolonged sedation and uncon-
sciousness have been observed after administration of diazepam
in CYP2C19 PMs (Bertilsson, 1995). In addition, a diminished
response to the antiplatelet drug clopidogrel has been found in
CYP2C19 PMs (Hulot et al., 2006; Brandt et al., 2007; Mega et al.,
2009). However, proton pump inhibitor drugs, including omepra-
zole and lansoprazole, exhibit a greater cure rate for gastric ulcers
with Helicobacter pylori infections in PMs than in EMs due to
higher plasma concentrations of the parent drugs in PMs (Sohn
et al., 1997; Furuta et al., 1998). In any case, clinical decision
strategies following CYP2C19 genotyping suggest two regimens:
an adjustment of the drug dose according to the genotype or an
alternative drug choice. However, the greatest uncertainty is in the
IM group, in which interindividual variation is clearly observed.
The underlying mechanism for this variation remains unclear.
Integration of other factors, such as clinical factors, environmen-
tal factors, and drug response-modulating factors may be needed
to understand this variation. A successful launch of personal-
ized medicine in relation to CYP2C19 drugs would be impossible
without resolving the variation in the IM group. The majority
of CYP2C19 pharmacogenetic studies have been conducted using
CYP2C19∗2, ∗3, and ∗17 variants. This article presents a collection
of functional CYP2C19 variants evidenced in human studies and
discusses their utilities and limitations for clinical use.
DIVERSE CYP2C19 FUNCTIONAL VARIANTS
Four CYP2C genes have been identified in humans: CYP2C8,
CYP2C9, CYP2C18, and CYP2C19. Among them, CYP2C19 is the
most polymorphic enzyme, and it metabolizes many important
clinical drugs. Its activity can be inhibited by fluoxetine (Jeppe-
sen et al., 1996), fluvoxamine (Jeppesen et al., 1996; Yao et al.,
2003), lansoprazole, pantoprazole (Li et al., 2004), and ticlopidine
(Tateishi et al., 1999), and can be induced by phenobarbital and
rifampin (Madan et al., 2003). A number of CYP2C19 polymor-
phisms have been identified. However, defining the quantitative
value of altered functionality of the identified variant, such as the
unequivocal percent value of wild-type activity, is difficult except
for null alleles. One reason for this difficulty is from the different
functional assay systems that include various molecular techniques
with lab-to-lab variations. For example, to study protein-coding
variants, enzyme expression systems have included yeast (Fergu-
son et al., 1998), baculovirus (Mankowski, 1999), and Escherichia
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coli (Lee et al., 2009), and have depended on the preference or
experimental conditions of the laboratory. All systems are useful
biochemical tools for determining relative activity compared to
wild-type activity in vitro. However, results of comparative para-
meters are not identical among the assay systems. In addition, not
all in vitro assay systems reflect the same phenomena of those con-
ditions in vivo. Therefore, a quantitative comparison of CYP2C19
variants with wild-type CYP2C19 has been difficult and should be
interpreted with great caution.
New CYP2C19 variants have been discovered by direct DNA
sequencing using two kinds of human DNA samples, normal
healthy subjects or phenotyped individuals. CYP2C19 variants
identified by DNA sequencing in individuals that have been char-
acterized by clinicians as PMs or outliers include CYP2C19∗2, ∗3,
∗4, ∗5, ∗6, ∗7, ∗8, ∗16, ∗17, and ∗26, all based on comparisons to
wild-type CYP2C19 activity in vivo or in in vitro functional studies,
with the exception of CYP2C19∗16 (Wilkinson et al., 1989; Balian
et al., 1995). Briefly, CYP2C19∗2 is the most common variant,
which is a single base pair mutation in exon 5 (G>A), result-
ing an aberrant splice site (de Morais et al., 1994b). Creation of
this splice site alters the reading frame of the mRNA beginning
at amino acid 215 and produces a premature stop codon of 20
amino acids downstream (de Morais et al., 1994b); in that study,
7 of 10 Caucasians and 10 of 17 Japanese PMs for mephenytoin
were homozygous for this mutation. CYP2C19∗3 has been found
in Japanese PMs that were not homozygous for CYP2C19∗2 (de
Morais et al., 1994a).CYP2C19∗3, the result of the 636G>A muta-
tion in exon 4, creates a premature stop codon. CYP2C19∗2 and ∗3
are responsible for the majority of PM phenotypes in the metab-
olism of CYP2C19 substrate drugs (Goldstein, 2001; Xie et al.,
2001). CYP2C19∗4, an A>G mutation in the initiation codon,
was identified in Caucasian PMs of mephenytoin (Ferguson et al.,
1998); in that study, CYP2C19∗4 cDNA was not expressed into
the protein in a yeast expression system or an in vitro translation
assay, whereas the CYP2C19∗1 cDNA was expressed and trans-
lated in both systems, suggesting a new PM allele. CYP2C19∗5,
a 1297C>T mutation in the heme-binding region, results in a
Arg433Trp substitution and has been identified in a single Chinese
PM of S-mephenytoin (Xiao et al., 1997) and 1 in 37 white PMs
of S-mephenytoin (Ibeanu et al., 1998a). A recombinant enzyme
activity study indicated that this allele abolishes the activity toward
S-mephenytoin and tolbutamide, suggesting a PM allele (Ibeanu
et al., 1998a). CYP2C19∗6, a 395G>A mutation in exon 3, leads
to an Arg132Gln substitution and has been found in a white PM
outlier of mephenytoin (Ibeanu et al., 1998b). In this study, recom-
binant protein of CYP2C19∗6 prepared in an E. coli expression
system exhibited negligible activity toward S-mephenytoin com-
pared to that of wild-type, indicating that the CYP2C19∗6 allele
contributes to the PM phenotype in whites. CYP2C19∗7 is a T>A
mutation at the 5′ donor splice site of intron 5 and results in a
PM allele. This allele has been found in a mephenytoin PM out-
lier of a Danish individual (Ibeanu et al., 1999). CYP2C19∗8, a
T358C change in exon 3 that results in a Trp120Arg substitu-
tion, was first identified in a French subject enrolled in a cancer
risk study with mephenytoin activity (Benhamou et al., 1997).
In a recombinant study, the CYP2C19∗8 protein exhibited a 90%
decrease in activity for S-mephenytoin and a 70% reduction in
tolbutamide activity compared to wild-type (Ibeanu et al., 1999).
CYP2C19∗16 is a 1324C>T change in exon 9 located close to the
heme-binding region that results in a Arg442Cys substitution, and
was first identified in a Japanese individual with a low capacity
to metabolize mephobarbital (Morita et al., 2004). Because this
amino acid change is located close to the heme-binding site, it is
proposed to have decreased activity for CYP2C19 substrate drugs.
CYP2C19∗17 is an allele carrying −806C>T and −3042C>T
found in the 5′ regulatory region (Sim et al., 2006). Individu-
als with CYP2C19∗17/∗17 exhibit 35–40% lower omeprazole area
under the plasma concentration-time curve values than the indi-
viduals havingCYP2C19∗1/∗1, suggesting that this allele leads to an
increased metabolizer phenotype. In Sim et al. (2006), a reporter
assay showed increased transcriptional activity of CYP2C19∗17
and electrophoretic mobility shift assays showed specific bind-
ing of human hepatic nuclear proteins to an element carrying
−806T but not −806C. CYP2C19∗26, a 766G>A change in exon
5 resulting in a D256N substitution, was first identified in an
omeprazole PM outlier of a Vietnamese individual; a recombi-
nant enzyme activity assay prepared in an E. coli expression system
showed a significant decrease in Vmax for omeprazole (2.6-fold)
and mephenytoin metabolism (twofold; Lee et al., 2009).
The majority of other alleles have been discovered in various
human projects by using DNAs obtained from normal popula-
tions. CYP2C19 variants that were discovered without phenotyp-
ing but which were characterized by in vitro systems include ∗9,
∗10, ∗11, ∗12, ∗13, ∗14, ∗15, and ∗27. A positive correlation between
in vitro data and in vivo biological evidence would strengthen the
incorporation of genetic data into clinical practice. Although more
than 2,000 variants have been identified in the last several decades,
alleles characterized via either in vivo or in vitro studies are lim-
ited to less than 20 variants, indicating a huge gap between the
number of discovered single nucleotide polymorphisms (SNPs)
and the number of functionally known SNPs. A summary of
CYP2C19 variants that have been discovered and characterized
in phenotyped human subjects is presented in Figure 1. Clini-
cal application of variant alleles with functional information is
critical in the clinical setting for individualized drug therapy.
Profiling of rare variants reflecting interindividual variability in
drug responses could be difficult, but is needed for incorporat-
ing CYP2C19 pharmacogenetics into the clinical decision making
process.
Because CYP2C19∗2 and CYP2C19∗3 are the most common
and defective variants (Goldstein et al., 1997; Xie et al., 2001), a
number of reports have described the clinical significance of these
variants. The promoter variant CYP2C19∗17 has been shown to
be associated with increased CYP2C19 activity due to increased
transcription of CYP2C19. Therefore, homozygous carriers of
CYP2C19∗17 exhibit rapid clearance of CYP2C19 substrate drugs
compared to wild-type (Sim et al., 2006; Ingelman-Sundberg et al.,
2007; Rudberg et al., 2008). As a consequence, individuals with
CYP2C19∗17 are likely to exhibit a lack of response to certain
PPIs and antidepressants compared to EMs (CYP2C19∗1/∗1); this
is due to rapid clearance of the drugs. Although most variation
in the drug response can be explained by these three variants
(CYP2C19∗2, ∗3, and ∗17 ), high interindividual variation in sub-
jects homozygous for CYP2C19∗1 has also been observed (Sim
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FIGURE 1 | Distribution of CYP2C19 variants discovered and
characterized in phenotyped human subjects and normal populations. A
total of 2,075 rsSNPs have been reported in NCBI CYP2C19 SNP database at
the present stage. Among them the number of SNPs that are functionally
studied in vitro and validated in vivo is limited. Proposed scheme is for the
personalized medicine of CYP2C19 substrate drugs.
et al., 2006). It is well-known that CYP2C19 activity is influenced
by clinical factors, various inducers and inhibitors, drug–drug
interactions, and other genetic polymorphisms in drug response-
related genes. Because most studies have translated drug response
data after genotyping for common alleles only, variants that have
not been detected may be missing. More candidate SNPs may
improve the translational process for drug responses. The limited
amount of genotyping in current research may be due to the lack
of data on the functional significance (in vitro or in vivo) of the
allele and the low or undetermined allele frequency in the study
population. Therefore, information on the functional significance
of the variant allele would help researchers to include more can-
didate SNPs for genotyping in their clinical studies. This would
ultimately improve translational quality in clinical settings and
would be a beginning step for launching personalized medicine
because physicians could easily communicate with patients using
biological evidence for the drug response prediction instead of
explaining the statistical risk without biological significance.
CURRENT CLINICAL UTILITIES OF CYP2C19
POLYMORPHISMS
Many clinical drugs are metabolized by CYP2C19, and hence, the
pharmacokinetics of CYP2C19 substrate drugs is influenced by
CYP2C19 polymorphisms. Altered CYP2C19 activity can be, at
least in part, predicted by theCYP2C19 genotype. The most exten-
sively used polymorphic variants for genotype and phenotype
association studies have been CYP2C19∗2, ∗3, and ∗17 (Goldstein,
2001; Xie et al., 2001; Desta et al., 2002). Ethnic differences in the
frequency of CYP2C19∗2, ∗3, and ∗17 alleles are summarized in
Table 1. Identification of PM alleles or the CYP2C19∗17 variant in
patients and the modification of therapy regimens does not repre-
sent personalized drug therapy but is useful for the prevention of
side effects. Because the human genome is very difficult to under-
stand and drug responses are affected by several modulating genes
with environmental factors, the development of personalized med-
icine for CYP2C19 substrate drugs using only CYP2C19 and
other modulating gene’s genotypes is nearly impossible. However,
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Table 1 | Frequencies of CYP2C19 *2, *3, and *17 alleles in different ethnic populations.
Ethnic group Allele no. *2 (681G>A) *3 (636G>A) *17 (−806C>T) Reference
Splicing defect W212X Increased transcription
WHITE
Faroese 622 0.187 N.D 0.154 Pedersen et al. (2010)
Danish 552 0.150 N.D 0.201 Pedersen et al. (2010)
French 48 0.208 N.D 0.188 Berge et al. (2011)
Italian 720 0.094 0.008 N.D Scordo et al. (2001)
Polish 250 0.116 N.D 0.272 Kurzawski et al. (2006)
Norwegian 664 0.181 0.006 0.220 Rudberg et al. (2008)
Sweden 370 0.160 N.D 0.200 Ramsjö et al. (2010)
Russians 580 0.114 0.003 N.D Gaikovitch et al. (2003)
Caucasian 284 0.136 0.000 0.201 Myrand et al. (2008)
BLACK
African-American 216 0.250 0.000 N.D Bravo-Villalta et al. (2005)
African-American 472 0.182 0.008 N.D Luo et al. (2006)
African-American 228 N.D N.D 0.210 Kearns et al. (2010)
Ethiopian 380 N.D N.D 0.179 Sim et al. (2006)
Nigerian 86 0.151 0.000 N.D Babalola et al. (2010)
Egyptians 494 0.110 0.002 N.D Hamdy et al. (2002)
ASIAN
Korean 542 0.284 0.101 0.015 Kim et al. (2010)
Korean 100 0.290 0.050 0.020 Lee et al. (2009)
Chinese 136 N.D N.D 0.044 Sim et al. (2006)
Chinese 800 0.247 0.033 0.012 Chen et al. (2008)
Japanese 530 0.279 0.128 0.013 Sugimoto et al. (2008)
Japanese 200 0.345 0.090 0.005 Myrand et al. (2008)
India 40 0.375 0.000 N.D. Lamba et al. (2000)
India 906 0.350 0.010 N.D. Jose et al. (2005)
Vietnamese 330 0.264 0.049 N.D. Lee et al. (2007)
Thai 1548 0.290 0.030 N.D. Tassaneeyakul et al. (2006)
Burmese 254 0.300 0.040 N.D. Tassaneeyakul et al. (2006)
Karen 262 0.280 0.010 N.D. Tassaneeyakul et al. (2006)
Jordanian 156 0.160 0.000 N.D. Zalloum et al. (2012)
Iranians 206 0.120 0.100 N.D. Hashemi-Soteh et al. (2012)
N.D., not determined.
several FDA-approved drugs are strongly affected by CYP2C19
genotypes (see Table 2), and their labels include pharmacoge-
nomic information (http://www.fda.gov/Drugs/ScienceResearch/
ResearchAreas/Pharmacogenetics). Briefly, diazepam is demethy-
lated by CYP2C19 (Jung et al., 1997), and hence its pharmaco-
kinetics are affected by CYP2C19 genetic polymorphisms. The
plasma half-life of diazepam is approximately fourfold longer in
individuals with PM genotypes than in individuals homozygous
for wild-type CYP2C19∗1 (Wan et al., 1996; Qin et al., 1999). PMs
may be at risk for toxic doses of diazepam and therefore more care
is required to determine the diazepam dose for such subjects, espe-
cially for certain ethnicities because the frequency of PM differs
between ethnic groups, being 3–6% in whites and blacks, 13–23%
in Asians, and 38–79% in Polynesians and Micronesians (Kaneko
et al., 1999; Xie et al., 2001). The CYP2C19 genotype affects the
metabolism of PPIs, resulting in altered cure rates for H. pylori
infection in peptic ulcer patients. In a previous study, the cure rate
of peptic or duodenal ulcers for Japanese patients that received
dual therapy with omeprazole (20 mg/day for 2 weeks) and amox-
icillin (2,000 mg/day for 2 weeks) was 100% in CYP2C19 PMs,
60% for those who were heterozygous for one mutant allele, and
29% in individuals homozygous for the CYP2C19∗1 allele (Furuta
et al., 1998). These differences are attributable to theCYP2C19 PM
genotype’s impaired metabolism of PPIs, which leads to higher PPI
plasma concentrations in PM individuals (Furuta et al., 2004). The
contribution of CYP2C19 to the metabolism of various PPIs dif-
fers. For example, in terms of plasma drug concentration-time
curves, the ratio of the area under the curve of PMs versus EMs
decreases in the following order: omeprazole, pantoprazole, lan-
soprazole, and rabeprazole (Funck-Brentano et al., 1997; Furuta
et al., 2004). This is in agreement with the fact that the cure rate of
rabeprazole is less dependent on theCYP2C19 genotype compared
to other PPIs. Patients with CYP2C19∗17 exhibit an enhanced
response to clopidogrel with an increased risk of bleeding due to
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Table 2 | Genetic polymorphisms in CYP2C19 and their clinical
consequences.
Drug Therapeutic area Clinical consequences
Diazepam Psychiatry Increased risk of sedation time and
unconsciousness in PM genotype due
to the prolonged half-life of diazepam
Omeprazole,
lansoprazole
Gastroenterology Increased cure rates due to increased
half-life of the parent drugs in PM
genotypes
Decreased cure rates in the EM
genotype
Clopidogrel Cardiovascular Decreased response to clopidogrel in
the PM genotype due to low
transformation into active metabolite
and increased risk of recurrent MI,
stroke, and stent thrombosis
Increased risk of bleeding disorder in
individuals homozygous for the
CYP2C19*17 allele due to increased
inhibition of platelet function
PM, poor metabolizer; EM, extensive metabolizer; MI, myocardial infarction.
the higher rate of biotransformation into the active metabolite
(Sibbing et al., 2010). In addition, an improved protective effect
of clopidogrel after myocardial infarction has been observed in
patients carrying the CYP2C19∗17 allele (Tiroch et al., 2010). The
major enzymes involved in the production of the active metabo-
lite of clopidogrel have been identified as CYP2C19, CYP3A4, and
paraoxonase-1 (Clarke and Waskell, 2003; Bouman et al., 2011),
although clopidogrel itself is a potent inhibitor of CYP2C19 and
CYP3A4 (Richter et al., 2004). In general, patients that carry one or
two CYP2C19 loss-of-function alleles exhibit diminished platelet
inhibition after clopidogrel treatment compared to those with
the EM genotype (Hulot et al., 2006; Brandt et al., 2007; Mega
et al., 2009; Kubica et al., 2011). CYP2C19 PMs may not bene-
fit from clopidogrel and thus alternative drugs, such as prasugrel,
should be considered. No definitive recommendations have been
established regarding dose adjustment of clopidogrel based on
CYP2C19 genotype testing. This may be due to the fact that other
downstream genes, such as GPIIb/IIIa receptor genes, and other
modulating factors can render a patient more sensitive or more
resistant to clopidogrel despite having the same genotype. Larger-
scale investigations using genotype-guided clopidogrel therapy
compared to other therapy options would reveal the effectiveness
of CYP2C19 genotype testing for clopidogrel therapy.
FUTURE DIRECTIONS FOR CLINICAL APPLICATION
To date, the pharmacogenetic data on CYP2C19 clearly support
that genetic variants alter the drug responses of its substrate drug.
However, clinical application of CYP2C19 pharmacogenetics is
limited to certain genotypes, mostly null alleles, and functionally
known variants with a minor allele frequency of >5%. Clinical
research using common variants only in case and control groups
can enhance the statistical power of the evidence for that vari-
ant. However, the number of study populations that would benefit
from pharmacogenomics research would be greatly reduced if such
studies focused on common variants for strong statistical evidence.
One goal of pharmacogenomics is to provide personalized med-
icine to each individual patient and to provide him or her an
appropriate dose of the most appropriate drug. Therefore, more
diversified investigations or strategies including low-frequency
variants are needed to develop a standard practice for human
applications. This may be ineffective or unrealistic for personal-
ized medicine if clinical trials wait for the enrollment of a certain
number of participants carrying the target genotype to satisfy the
statistical power when assessing the role of that particular variant.
The biological function of most rare variants remains unknown
or has not been investigated in vitro, which has made physicians
reluctant to test these individuals in clinical trials. Therefore, more
data on functional genomics are needed particularly for rare vari-
ants. Although CYP2C19 is a major enzyme for the metabolism
of certain drugs and influences their pharmacokinetics, there are
many other genes that can modulate or mask the genetic effect of
CYP2C19 polymorphisms, including genes involved in pharma-
codynamics. Fortunately, recent whole genome sequencing and
exome sequencing data have identified numerous variants, and
these findings have led to genome-wide association studies using
dense genomic markers on chips, resulting in the discovery of new
determinants of drug responses. In conclusion, the translation of
CYP2C19 pharmacogenetics into clinical practice is currently lim-
ited to a small number of functional variants, although more than
2,000 variants have already been discovered. More comprehensive
and diverse research covering a large number of CYP2C19 variants
will lay the foundation for improved personalized medicine in the
future.
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